COSMO PHARMACEUTICALS NV (C43.DE) Stock Price & Overview
FRA:C43 • NL0011832936
Current stock price
The current stock price of C43.DE is 48.8 EUR. Today C43.DE is down by -2.4%. In the past month the price decreased by -17.98%. In the past year, price decreased by -32.22%.
C43.DE Key Statistics
- Market Cap
- 855.952M
- P/E
- 5.98
- Fwd P/E
- 8.09
- EPS (TTM)
- 8.16
- Dividend Yield
- 3.85%
C43.DE Stock Performance
C43.DE Stock Chart
C43.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to C43.DE. When comparing the yearly performance of all stocks, C43.DE is a bad performer in the overall market: 94.45% of all stocks are doing better.
C43.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE. C43.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
C43.DE Earnings
C43.DE Forecast & Estimates
10 analysts have analysed C43.DE and the average price target is 104.72 EUR. This implies a price increase of 114.58% is expected in the next year compared to the current price of 48.8.
For the next year, analysts expect an EPS growth of -23.67% and a revenue growth -19.4% for C43.DE
C43.DE Groups
Sector & Classification
C43.DE Financial Highlights
Over the last trailing twelve months C43.DE reported a non-GAAP Earnings per Share(EPS) of 8.16. The EPS increased by 1315.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 49.94% | ||
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| Debt/Equity | 0 |
C43.DE Ownership
C43.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.54 | 98.029B | ||
| SNW | SANOFI | 9.54 | 98.005B | ||
| 1SAN | SANOFI | 9.5 | 97.617B | ||
| UCB | UCB SA | 26.43 | 52.09B | ||
| UNC | UCB SA | 25.88 | 51.779B | ||
| MRK | MERCK KGAA | 13.47 | 49.087B | ||
| 1MRK | MERCK KGAA | 12.99 | 46.695B | ||
| BAYN | BAYER AG-REG | 8.64 | 39.768B | ||
| 1BAYN | BAYER AG-REG | 8.63 | 39.68B | ||
| IPN | IPSEN | 13.33 | 13.669B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.99 | 10.39B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.89B | ||
| VIRP | VIRBAC SA | 16.46 | 2.983B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About C43.DE
Company Profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 322 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Company Info
IPO: 2016-05-18
COSMO PHARMACEUTICALS NV
Riverside II, Sir John Rogerson's Quay
DUBLIN DUBLIN IE
Employees: 322
Phone: 35318170370
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What does C43 do?
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 322 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Breezula (clascoterone), GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, CB-01-33 (colesevelam), and CB-01-35. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travelers’ diarrhea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
What is the current price of C43 stock?
The current stock price of C43.DE is 48.8 EUR. The price decreased by -2.4% in the last trading session.
What is the dividend status of COSMO PHARMACEUTICALS NV?
COSMO PHARMACEUTICALS NV (C43.DE) has a dividend yield of 3.85%. The yearly dividend amount is currently 2.
What is the ChartMill technical and fundamental rating of C43 stock?
C43.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 9 out of 10.
How is the market expecting C43 stock to perform?
10 analysts have analysed C43.DE and the average price target is 104.72 EUR. This implies a price increase of 114.58% is expected in the next year compared to the current price of 48.8.
Can you provide the sector and industry classification for COSMO PHARMACEUTICALS NV?
COSMO PHARMACEUTICALS NV (C43.DE) operates in the Health Care sector and the Pharmaceuticals industry.